Epigenetics in the treatment of systemic lupus erythematosus: Potential clinical application
The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Guo, Yu [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014transfer abstract |
|---|
| Umfang: |
12 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Comorbid episodes of primary bruxism and bruxism as an epileptic activity-related motor event - Bušková, Jitka ELSEVIER, 2019, San Diego, Calif |
|---|---|
| Übergeordnetes Werk: |
volume:155 ; year:2014 ; number:1 ; pages:79-90 ; extent:12 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.clim.2014.09.002 |
|---|
| Katalog-ID: |
ELV039213994 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV039213994 | ||
| 003 | DE-627 | ||
| 005 | 20230625224330.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clim.2014.09.002 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014005000001.pica |
| 035 | |a (DE-627)ELV039213994 | ||
| 035 | |a (ELSEVIER)S1521-6616(14)00213-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.90 |2 bkl | ||
| 100 | 1 | |a Guo, Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Epigenetics in the treatment of systemic lupus erythematosus: Potential clinical application |
| 264 | 1 | |c 2014transfer abstract | |
| 300 | |a 12 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications. | ||
| 520 | |a The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications. | ||
| 700 | 1 | |a Sawalha, Amr H. |4 oth | |
| 700 | 1 | |a Lu, Qianjin |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Bušková, Jitka ELSEVIER |t Comorbid episodes of primary bruxism and bruxism as an epileptic activity-related motor event |d 2019 |g San Diego, Calif |w (DE-627)ELV003196453 |
| 773 | 1 | 8 | |g volume:155 |g year:2014 |g number:1 |g pages:79-90 |g extent:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.clim.2014.09.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.90 |j Neurologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 155 |j 2014 |e 1 |h 79-90 |g 12 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
y g yg |
|---|---|
| matchkey_str |
guoyusawalhaamrhluqianjin:2014----:pgntciteramnosseilpsrteaouptni |
| hierarchy_sort_str |
2014transfer abstract |
| bklnumber |
44.90 |
| publishDate |
2014 |
| allfields |
10.1016/j.clim.2014.09.002 doi GBVA2014005000001.pica (DE-627)ELV039213994 (ELSEVIER)S1521-6616(14)00213-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.90 bkl Guo, Yu verfasserin aut Epigenetics in the treatment of systemic lupus erythematosus: Potential clinical application 2014transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications. The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications. Sawalha, Amr H. oth Lu, Qianjin oth Enthalten in Elsevier Bušková, Jitka ELSEVIER Comorbid episodes of primary bruxism and bruxism as an epileptic activity-related motor event 2019 San Diego, Calif (DE-627)ELV003196453 volume:155 year:2014 number:1 pages:79-90 extent:12 https://doi.org/10.1016/j.clim.2014.09.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.90 Neurologie VZ AR 155 2014 1 79-90 12 045F 610 |
| spelling |
10.1016/j.clim.2014.09.002 doi GBVA2014005000001.pica (DE-627)ELV039213994 (ELSEVIER)S1521-6616(14)00213-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.90 bkl Guo, Yu verfasserin aut Epigenetics in the treatment of systemic lupus erythematosus: Potential clinical application 2014transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications. The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications. Sawalha, Amr H. oth Lu, Qianjin oth Enthalten in Elsevier Bušková, Jitka ELSEVIER Comorbid episodes of primary bruxism and bruxism as an epileptic activity-related motor event 2019 San Diego, Calif (DE-627)ELV003196453 volume:155 year:2014 number:1 pages:79-90 extent:12 https://doi.org/10.1016/j.clim.2014.09.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.90 Neurologie VZ AR 155 2014 1 79-90 12 045F 610 |
| allfields_unstemmed |
10.1016/j.clim.2014.09.002 doi GBVA2014005000001.pica (DE-627)ELV039213994 (ELSEVIER)S1521-6616(14)00213-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.90 bkl Guo, Yu verfasserin aut Epigenetics in the treatment of systemic lupus erythematosus: Potential clinical application 2014transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications. The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications. Sawalha, Amr H. oth Lu, Qianjin oth Enthalten in Elsevier Bušková, Jitka ELSEVIER Comorbid episodes of primary bruxism and bruxism as an epileptic activity-related motor event 2019 San Diego, Calif (DE-627)ELV003196453 volume:155 year:2014 number:1 pages:79-90 extent:12 https://doi.org/10.1016/j.clim.2014.09.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.90 Neurologie VZ AR 155 2014 1 79-90 12 045F 610 |
| allfieldsGer |
10.1016/j.clim.2014.09.002 doi GBVA2014005000001.pica (DE-627)ELV039213994 (ELSEVIER)S1521-6616(14)00213-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.90 bkl Guo, Yu verfasserin aut Epigenetics in the treatment of systemic lupus erythematosus: Potential clinical application 2014transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications. The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications. Sawalha, Amr H. oth Lu, Qianjin oth Enthalten in Elsevier Bušková, Jitka ELSEVIER Comorbid episodes of primary bruxism and bruxism as an epileptic activity-related motor event 2019 San Diego, Calif (DE-627)ELV003196453 volume:155 year:2014 number:1 pages:79-90 extent:12 https://doi.org/10.1016/j.clim.2014.09.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.90 Neurologie VZ AR 155 2014 1 79-90 12 045F 610 |
| allfieldsSound |
10.1016/j.clim.2014.09.002 doi GBVA2014005000001.pica (DE-627)ELV039213994 (ELSEVIER)S1521-6616(14)00213-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.90 bkl Guo, Yu verfasserin aut Epigenetics in the treatment of systemic lupus erythematosus: Potential clinical application 2014transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications. The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications. Sawalha, Amr H. oth Lu, Qianjin oth Enthalten in Elsevier Bušková, Jitka ELSEVIER Comorbid episodes of primary bruxism and bruxism as an epileptic activity-related motor event 2019 San Diego, Calif (DE-627)ELV003196453 volume:155 year:2014 number:1 pages:79-90 extent:12 https://doi.org/10.1016/j.clim.2014.09.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.90 Neurologie VZ AR 155 2014 1 79-90 12 045F 610 |
| language |
English |
| source |
Enthalten in Comorbid episodes of primary bruxism and bruxism as an epileptic activity-related motor event San Diego, Calif volume:155 year:2014 number:1 pages:79-90 extent:12 |
| sourceStr |
Enthalten in Comorbid episodes of primary bruxism and bruxism as an epileptic activity-related motor event San Diego, Calif volume:155 year:2014 number:1 pages:79-90 extent:12 |
| format_phy_str_mv |
Article |
| bklname |
Neurologie |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Comorbid episodes of primary bruxism and bruxism as an epileptic activity-related motor event |
| authorswithroles_txt_mv |
Guo, Yu @@aut@@ Sawalha, Amr H. @@oth@@ Lu, Qianjin @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV003196453 |
| dewey-sort |
3610 |
| id |
ELV039213994 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV039213994</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625224330.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.clim.2014.09.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014005000001.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV039213994</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1521-6616(14)00213-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.90</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Guo, Yu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Epigenetics in the treatment of systemic lupus erythematosus: Potential clinical application</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sawalha, Amr H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lu, Qianjin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Bušková, Jitka ELSEVIER</subfield><subfield code="t">Comorbid episodes of primary bruxism and bruxism as an epileptic activity-related motor event</subfield><subfield code="d">2019</subfield><subfield code="g">San Diego, Calif</subfield><subfield code="w">(DE-627)ELV003196453</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:155</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:79-90</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.clim.2014.09.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.90</subfield><subfield code="j">Neurologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">155</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="h">79-90</subfield><subfield code="g">12</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Guo, Yu |
| spellingShingle |
Guo, Yu ddc 610 bkl 44.90 Epigenetics in the treatment of systemic lupus erythematosus: Potential clinical application |
| authorStr |
Guo, Yu |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV003196453 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.90 bkl Epigenetics in the treatment of systemic lupus erythematosus: Potential clinical application |
| topic |
ddc 610 bkl 44.90 |
| topic_unstemmed |
ddc 610 bkl 44.90 |
| topic_browse |
ddc 610 bkl 44.90 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a h s ah ahs q l ql |
| hierarchy_parent_title |
Comorbid episodes of primary bruxism and bruxism as an epileptic activity-related motor event |
| hierarchy_parent_id |
ELV003196453 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Comorbid episodes of primary bruxism and bruxism as an epileptic activity-related motor event |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV003196453 |
| title |
Epigenetics in the treatment of systemic lupus erythematosus: Potential clinical application |
| ctrlnum |
(DE-627)ELV039213994 (ELSEVIER)S1521-6616(14)00213-7 |
| title_full |
Epigenetics in the treatment of systemic lupus erythematosus: Potential clinical application |
| author_sort |
Guo, Yu |
| journal |
Comorbid episodes of primary bruxism and bruxism as an epileptic activity-related motor event |
| journalStr |
Comorbid episodes of primary bruxism and bruxism as an epileptic activity-related motor event |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
79 |
| author_browse |
Guo, Yu |
| container_volume |
155 |
| physical |
12 |
| class |
610 610 DE-600 610 VZ 44.90 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Guo, Yu |
| doi_str_mv |
10.1016/j.clim.2014.09.002 |
| dewey-full |
610 |
| title_sort |
epigenetics in the treatment of systemic lupus erythematosus: potential clinical application |
| title_auth |
Epigenetics in the treatment of systemic lupus erythematosus: Potential clinical application |
| abstract |
The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications. |
| abstractGer |
The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications. |
| abstract_unstemmed |
The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
1 |
| title_short |
Epigenetics in the treatment of systemic lupus erythematosus: Potential clinical application |
| url |
https://doi.org/10.1016/j.clim.2014.09.002 |
| remote_bool |
true |
| author2 |
Sawalha, Amr H. Lu, Qianjin |
| author2Str |
Sawalha, Amr H. Lu, Qianjin |
| ppnlink |
ELV003196453 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.clim.2014.09.002 |
| up_date |
2024-07-06T20:03:54.854Z |
| _version_ |
1803861344760365056 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV039213994</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625224330.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.clim.2014.09.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014005000001.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV039213994</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1521-6616(14)00213-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.90</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Guo, Yu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Epigenetics in the treatment of systemic lupus erythematosus: Potential clinical application</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The current treatments of systemic lupus erythematosus (SLE) have been based on the use of immunosuppressive drugs which are linked to serious side effects. The more effective therapeutic approaches with minimal or no side effects for SLE patients are hard to develop, mainly due to the complexity of the disease. The discovery of pharmacoepigenetics provides a new way to solve this problem. Epigenetic modifications can influence drug efficacy by altering gene expression via changing chromatin structure. Although still in early development, epigenetic studies in SLE are expected to reveal novel therapeutic targets and disease biomarkers in autoimmunity. For example, miRNAs, which have been identified to govern many genes including drug targets, are altered in disease development and after drug administration. This review aims to present an overview of current epigenetic mechanisms involved in the pathogenesis of SLE, and discuss their potential roles in clinical and pharmacological applications.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sawalha, Amr H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lu, Qianjin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Bušková, Jitka ELSEVIER</subfield><subfield code="t">Comorbid episodes of primary bruxism and bruxism as an epileptic activity-related motor event</subfield><subfield code="d">2019</subfield><subfield code="g">San Diego, Calif</subfield><subfield code="w">(DE-627)ELV003196453</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:155</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:79-90</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.clim.2014.09.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.90</subfield><subfield code="j">Neurologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">155</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="h">79-90</subfield><subfield code="g">12</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4013977 |